Nevirapine Viatris

Nevirapine, the active ingredient in Nevirapine Viatris, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It belongs to the antiretroviral therapeutic class and is typically used as part of combination regimens to achieve viral suppression. It is indicated for the treatment of HIV‑1 infection in both adults and children.

GNH USA supplies Nevirapine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to stringent quality standards and providing the product to hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral medication used in the management of HIV‑1 infection. - HIV‑1 infection (adults): Reduces viral load and improves immune function when used in combination therapy. - HIV‑1 infection (children): Enables viral suppression in pediatric patients as part of approved regimens. - Prevention of mother‑to‑child transmission: Decreases the risk of vertical transmission when administered during pregnancy and delivery.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal discomfort. - Fatigue: feeling of tiredness or weakness. - Headache: transient cranial pain. - Abdominal pain: mild stomach discomfort.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate discontinuation. - Hepatotoxicity: elevated liver enzymes or liver failure. - Severe hypersensitivity: fever, eosinophilia, or organ involvement. - Neutropenia: marked reduction in white blood cells. - Anaphylaxis: rare life‑threatening allergic reaction.

Before initiating therapy, clinicians should assess patient history and monitor for potential risks. - Monitor liver function: Perform baseline and periodic liver enzyme tests due to hepatotoxicity risk. - Observe for rash: Discontinue immediately if severe skin reactions develop. - Avoid strong CYP3A inducers: These can lower nevirapine exposure and reduce efficacy. - Use caution in hepatic impairment: Adjust therapy based on liver function status. - Store at ambient temperature below 25°C: Keep in the original container, protect from moisture and light.

Nevirapine interacts with several medicines, requiring careful management.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: May increase nevirapine levels and cause toxicity. - St. John’s wort: Induces metabolism, markedly reducing nevirapine effectiveness. - Efavirenz: Combined use can heighten hepatotoxic risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., certain statins): May need dose adjustment. - Oral contraceptives: Reduced hormonal efficacy; consider alternative contraception. - Methadone: May require dose increase to maintain therapeutic effect.